---
# System prepended metadata

title: Untitled

---

Global Influenza Vaccine Market
 
 ![](https://i.imgur.com/lN32Y2B.jpg)


Global Influenza Vaccine Market Insights
The Global Influenza Vaccine Market size was valued at USD 5.25 Billion in 2021, and it is expected to reach a value of USD 8.48 Billion by 2028, at a CAGR of 7.10% over the forecast period (2022 - 2028).
The influenza virus circulates continue indefinitely, causing regional epidemics and outbreaks that have resulted in thousands of deaths. For instance, according to data from the Centers for Disease Control and Prevention (CDC), more than 13 million flu cases have been recorded in the 2019-20 timeframe. The changing nature of the virus necessitates an annual change in the vaccine strain to match the influenza virus strain around the world. During the forecasted period, the increasing prevalence of influenza epidemics and seasonal outbreaks is expected to boost product sales.

Know more about : https://skyquestt.com/report/Influenza-vaccine-market 

Global Influenza Vaccine Market Segmental Analysis
The Global Influenza Vaccine Market is segmented based on type, valency, Age-group, distribution channel, and region. Based on type it is categorized into Inactivated and Live Attenuated. Based on valency it is categorized into Quadrivalent and Trivalent. Based on age group it is categorized into Pediatric and Adults. Based on distribution channel it is categorized into hospital & retail pharmacies, government, and others. Based on the region it is categorized into North America, Europe, Asia-Pacific, South America, and MEA.

Top Players Company Profiles
•	GlaxoSmithKline plc. (UK)
•	Sanofi S.A (France)
•	AstraZeneca (UK)
•	Seqirus (UK)
•	BioDiem (Australia)
•	Emergent BioSolutions Inc. (US)
•	Sinovac Biotech Ltd (China)
•	Novartis Ag (Switzerland)
•	Pfizer, Inc. (US)
•	Sinovac Biotech Ltd. (China)

Get free sample pdf report copy at : https://skyquestt.com/sample-request/Influenza-vaccine-market 

Recent Developments
•	In June 2022, Sanofi restructured its immuno-oncology collaboration with Regeneron Pharmaceuticals, Inc. Regeneron will have worldwide exclusive licensing rights to Libtayo under the modified and restated license and partnership agreement.
•	In May 2022, GSK plc announced that it has entered into a final agreement to acquire Affinivax, Inc. (Affinivax), a clinical-stage biopharmaceutical business located in Cambridge, Boston, Massachusetts, for a $2.1 billion upfront payment and up to $1.2 billion in possible development milestones.
•	In May 2021, During the pandemic, Australia launched a national flu vaccination programme to reduce the population's infection rate. As a result, seasonal vaccines are now available in Australia through community pharmacies and general practitioners.
•	In March 2021, Sanofi announced USD 736.9 million investment in its Canadian vaccine facility to increase supply of influenza vaccines in Canada, the United States, and Europe. With the goal of increasing supply in these countries, this facility will provide additional antigen and filling capacity for Sanofi's Fluzone High-Dose Quadrivalent influenza vaccine.

